Company Description
TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms.
Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines.
The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation.
The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy.
The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs.
TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024.
The company was founded in 2014 and is headquartered in Baltimore, Maryland.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Ian Rhodes CPA |
Contact Details
Address: 855 N. Wolfe Street, Suite 623 Baltimore, Maryland 21205 United States | |
| Phone | 856 848 8698 |
| Website | tnfpharma.com |
Stock Details
| Ticker Symbol | TNFA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001321834 |
| CUSIP Number | 62856X201 |
| ISIN Number | US62856X2018 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mitchell Glass M.D. | President, Chief Medical Officer and Director |
| Ian Rhodes CPA | Interim Chief Financial Officer |
| Robert Schatz | Investor Relations Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 21, 2025 | ARS | Filing |
| Apr 21, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 11, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 11, 2025 | 8-K | Current Report |
| Apr 11, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 21, 2025 | 8-K | Current Report |
| Mar 10, 2025 | 8-K | Current Report |
| Nov 26, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |